15 June 2018 - - Menlo Park, California-based diagnostic systems developer Talis Biomedical has received an award of up to USD 5.6m (over the next five years) from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the company said.
The award will fund development of a rapid, sensitive, and specific diagnostic system for the culture-independent identification and determination of antimicrobial susceptibility of bacterial pathogens from whole blood.
Talis is developing a high-performance diagnostic platform to enable physician offices and clinics to run reference lab quality diagnostic tests for infectious diseases at the point-of-care.
Point-of-care diagnostic platforms that can measure the drug susceptibility of a pathogen directly from clinical samples, eliminating lengthy procedures that require microbial growth can help in the fight against antibiotic resistant organisms.
The Talis system leverages proprietary isothermal amplification chemistries, innovative engineering and data science tools. The rapid, digital quantification capability of the company's proprietary SlipChip technology of parallel processing of thousands of nanoliter volume chambers will enable pathogen identification and susceptibility to antibiotics in less than two hours.
Talis is developing a new class of diagnostic systems to enable rapid, point of care testing across a wide range of healthcare settings. From the doctor's office to the hospital bedside to remote care settings, we are re-defining the treatment of infectious diseases.